Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis

Published:2019-07-09 Issue:8 Volume:12 Page:815-824
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Genuino Anne Julienne¹,Chaikledkaew Usa¹²,The Due Ong¹,Reungwetwattana Thanyanan³,Thakkinstian Ammarin¹⁴

Affiliation:

1. Faculty of Pharmacy, Faculty of Medicine Ramathibodi Hospital, Faculty of Medicine Siriraj Hospital, Faculty of Public Health, Faculty of Social Sciences and Humanities, Institute for Population and Social Research, Faculty of Graduate Studies, Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Bangkok, Thailand

2. Social Administrative Excellence Research (SAPER) Unit, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand

3. Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

4. Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Funder

Bill and Melinda Gates Foundation

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://tandfonline.com/doi/pdf/10.1080/17512433.2019.1637252

Reference35 articles.

1. World Health Organization International Agency for Research on Cancer. GLOBOCAN 2012: estimated Cancer incidence, mortality and prevalence worldwide 2012 [cited 2017 Mar 23]; Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

2. Cancer survival in five continents: a worldwide population-based study (CONCORD)

3. The Distinctive Nature of HER2-Positive Breast Cancers

4. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating the replicability of highly cited clinical research (2004–2018);PLOS ONE;2024-08-07

2. Adjuvant and Neoadjuvant Therapy for Breast Cancer: A Systematic Review;European Journal of Breast Health;2024-07-01

3. Trastuzumab‐induced toxic epidermal necrolysis in a Her‐2‐positive metastatic breast cancer patient—A rare case report;Clinical Case Reports;2024-06-23

4. A review of therapeutic agents for breast cancer with potentially radiosensitizing properties;Radiation Medicine and Protection;2024-06

5. Mapping breast and prostate cancer in the Brazilian public health system: study protocol of the Onco-Genomas Brasil;Frontiers in Oncology;2024-03-13